Cargando…
Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
BACKGROUND: Pancreatic cancer is the fourth largest cause of cancer death in the United States and Europe with over 100,000 deaths per year in Europe alone. The overall 5-year survival ranges from 2–7 % and has hardly improved over the last two decades. Approximately 15 % of all patients have resect...
Autores principales: | Versteijne, Eva, van Eijck, Casper H. J., Punt, Cornelis J. A., Suker, Mustafa, Zwinderman, Aeilko H., Dohmen, Miriam A. C., Groothuis, Karin B. C., Busch, Oliver R. C., Besselink, Marc G. H., de Hingh, Ignace H. J. T., ten Tije, Albert J., Patijn, Gijs A., Bonsing, Bert A., de Vos-Geelen, Judith, Klaase, Joost M., Festen, Sebastiaan, Boerma, Djamila, Erdmann, Joris I., Molenaar, I. Quintus., van der Harst, Erwin, van der Kolk, Marion B., Rasch, Coen R. N., van Tienhoven, Geertjan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784417/ https://www.ncbi.nlm.nih.gov/pubmed/26955809 http://dx.doi.org/10.1186/s13063-016-1262-z |
Ejemplares similares
-
Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer: The dummy run
por: Versteijne, Eva, et al.
Publicado: (2017) -
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
por: Janssen, Q. P., et al.
Publicado: (2021) -
Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022) -
Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials
por: Doppenberg, Deesje, et al.
Publicado: (2023) -
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
por: van Dam, J. L., et al.
Publicado: (2023)